

## Lactobacillus Reuteri's Significance in Women's Health and Infants

Sakshi V. Bhope<sup>\*</sup>, Shivani O. Nasare, Chetna P. Hiwase, Kalyanee D. Nirmal

*Kdk College of Pharmacy and Research Institute, Nandanvan, Nagpur, Maharashtra-440009, India.*

Date of Submission: 25-08-2024

Date of Acceptance: 05-09-2024

**ABSTRACT:** A probiotic with broad-spectrum antibacterial action is *Lactobacillus reuteri*. In addition to secreting enzymes and lactic acid, it possesses the traits of lactic acid bacteria and is also capable of producing reuterin, a broad-spectrum antibacterial agent consisting of 3-hydroxypropionaldehyde (3-HPA). Because 3-HPA may efficiently inhibit bacteria, yeasts, fungus, and pathogens, it is frequently used as an antiseptic and in the treatment of many diseases. Humans have *L. reuteri* in several body locations, such as the skin, gastrointestinal tract, urinary tract, and breast milk. Various people have various levels of *L. reuteri* abundance. There have been several reported advantages of *L. reuteri*.

### INTRODUCTION:

A diverse assemblage of commensal bacteria makes up the human microbiota. The gut microbiota is more numerous and diversified in terms of metabolism and genetic makeup than the entire human body. The human microbiota, in particular the gut microbiota (which includes over 90% of all commensals), has profound effects on the host's body's growth and maintenance, including immunological control, metabolism, and neuronal function. (1). The gut microbiota coevolves with the host's metabolic and neurological programming from birth onwards. The synergy between the infant's gut microbes is established from birth and forms throughout the early years of life. immune system and prevents the colonization of pathogens (2). Environmental factors including diet and lifestyle have a complicated relationship with the host that affects the development of the gut microbiota. (3). Therefore, the dynamics of this community within the host and any potential links it may have with disease risks can be illuminated by studying the gut microbiota from infancy to old age. Probiotics are administered to alleviate a number of health issues, indicating the great potential of probiotic applications in disease cure, partially through gut microbial composition rebalancing. (4). Probiotics

that produce lactic acid, such as various *Lactobacillus* species, have perhaps been the subject of the most research, both in children and adults. Numerous gastrointestinal (GI) tract problems may be prevented and treated with lactobacilli, according to preclinical and animal research. *Lactobacillus reuteri* benefits the host in a number of ways. (4, 5). Since its initial isolation in 1962, *L. reuteri* has been described as a heterofermentative species that colonizes both human and animal gastrointestinal tracts and flourishes in environments with low oxygen levels. Its probiotic qualities might stem from the fact that it typically colonizes the GI tract. Humans have *L. reuteri* in several body locations, including as the skin, GI tract, urinary tract, and breast milk. (5) The role of *Lactobacillus reuteri* in maintaining mucosal homeostasis and controlling the gut microbiota has been investigated in a number of clinical investigations. In pathological situations, the metabolites generated by *L. reuteri* reduce intestinal inflammation and have an impact on the intestinal host immune system. This range of roles illustrates the dual benefit that *L. reuteri* provides to human immunity and intestinal health. (5) For a probiotic strain to colonize, interact with host cells, suppress pathogenic growth, protect epithelial cells, or modify the immune system, it must adhere to the GI tract of the host. (6). The ability of *L. reuteri* to adhere to intestinal epithelial cells and colonize mucin has been demonstrated in numerous investigations. Surface proteins, exopolysaccharide, inulosucrase, mucus-binding protein, D-alanyl-LTA, and glucosyltransferase A have all been connected to the likely mechanism behind adhesion. (4). *L. reuteri* can adhere to intestinal epithelia and mucin in its host with success (7). The intestinal barrier is strengthened when *L. reuteri* colonizes an area because it reduces the amount of microbes that move from the gut lumen to the surrounding tissues. Inflammation may have originated from microbial translocation across the gut epithelium.

### Probiotics:

According to the World Health Organization, probiotics are defined as “live microorganisms which, when administered in adequate amounts, confer a health benefit on the host”. These probiotics, that have already been proven to exert a beneficial impact, include *Saccharomyces boulardii*, *Lactobacillus* spp., *Bifidobacterium* spp., *Propionibacterium* spp., *Streptococcus* spp., *Bacillus* spp., *Enterococcus* spp., and some specific strains of *Escherichia coli* etc, in which *Lactobacillus* spp. is the most widely used in human nutrition. Recently, numerous bodies of research demonstrated that probiotics are beneficial for various diseases, such as intestinal disorders, respiratory tract infections, vaginal diseases, and so on. With the development of the food and drug industries and the innovation of technology, an increasing number of emerging probiotic strains were developed and applied to different fields, including natural food preservatives, nutraceuticals, and so on. Some novel technologies can also enhance probiotic products’ quality and sensory characteristics, which can contribute to the extensive application of probiotics. Safety is also an essential issue during the process of investigating probiotics. An ocean of evidence indicated that the use of probiotics can cause some risks regarding systemic infections, deleterious metabolic activities, excessive immune stimulation in susceptible individuals, gastrointestinal side effects, and so on. Some probiotic microorganisms can even transfer resistance genes to protect against antibiotics, which may be responsible for the development of the antibiotic resistance crisis. Taken together, the application of probiotics is a double-edged sword. Before probiotics are used, we still need to carry out enough clinical trials and animal experiments to assess their benefits and harms. *Lactobacillus* spp., which can be found in various food products, is one of the most widely used probiotics, and includes *Lactobacillus acidophilus*, *Lactobacillus rhamnosus*, *Lactobacillus bulgaricus*, *Lactobacillus casei*, and *Lactobacillus reuteri* (*L. reuteri*). *Lactobacillus reuteri* is a gut symbiont mainly colonized in the intestines of humans, rodents, pigs, and chickens. Since first isolated in 1962, there have been a great number of studies conducted on *L. reuteri* to explore its functions and concrete mechanisms in different diseases, which cover gastrointestinal diseases, hypercholesterolemia, skin infection, allergic asthma, periodontitis, hand, foot, and mouth disease (HFMD), and so on. Among these, there is an increasingly prevalent

trend that the investigations of *L. reuteri* in terms of intestinal diseases are becoming far and away the best area, which mainly concentrates on inflammatory bowel disease (IBD), colorectal cancer (CRC), children’s functional bowel diseases, and so on. (2)

Probiotics are defined as “live microorganisms which, when administered in adequate amounts, confer a health benefit on the host” by the World Health Organization (WHO)” [8] Those probiotics having beneficial properties include *Lactobacillus* species pluralis (spp), bifid bacterium spp., *Streptococcus* spp., *Bacillus* spp., *Enterococcus* spp., and some strains of *Escherichia coli*. “A common mechanism in probiotics includes colonization, producing short chain fatty acid, regulating intestinal transit, normalizing perturbed microbiota and exclusion of pathogens. Some probiotic strains can improve host food digestion by metabolizing bile salt or supplementing the functions of missing digestive enzymes” [9]. “*L. reuteri* is a probiotic bacteria found in body sites, including the GI tract, urinary tract, skin, and breast milk. The *L. reuteri* inhibits the colonization of pathogenic microbes and remodel the microbiota composition in the host. The colonization of *L. reuteri* may decrease the microbial translocation from the gut lumen to the tissues” [10].

Infant colic is a distressing condition characterized by crying and/or fussing of unknown cause that affects up to 28% of infants under three months of age. Etiology of infant colic is unclear and there is no widely accepted or effective treatment. Several studies have found differences in gastrointestinal (GI) microbial diversity between infants with colic and healthy infants, suggesting that an aberrant microbial intestinal profile may cause or contribute to infant colic. Infants with colic have higher rates and densities of *Escherichia coli* and other gas-producing coliforms and lower levels of *Lactobacillus* spp. compared with healthy infants, with some aerobic bacterial genera not detected in infants with colic. One study found that infants with colic had lower microbial diversity and elevated fecal calprotectin (a marker of gut inflammation) compared with healthy infants. However, another study found no difference in fecal calprotectin levels between healthy infants and infants with colic. [4]

The immature neonatal fecal microbiota substantially impacts the development of gut health and greatly increases the risk of disease. Developing effective strategies to modulate the development of neonatal fecal microbiota has great significance. Herein, we investigated whether the

maternal dietary supplementation and oral administration of *Lactobacillus reuteri* could effectively promote the development and maturation of the fecal microbiome in piglets from birth to weaning. [5]

Tannock (11) proposed that the 'ideal probiotic' should possess the following characteristics. It should persist for a long time in the GI tract and produce substances that inhibit gastrointestinal pathogens or stimulate immunity so as to increase the host's resistance to intestinal infections. It should contribute to the host's nutrition by synthesizing essential nutrients and/or by digesting dietary substances (e.g., lactose) that the host may be physiologically ill-equipped to utilize. It should be amenable to large-scale commercial production, be safe and devoid of characteristics that could compromise the host's health, and it should exhibit stability in all the above characteristics. He theorized, however, that attempts to isolate such an ideal probiotic strain would most likely fail, and that an alternative stratagem would be to derive such a strain by genetic manipulation. On a somewhat more optimistic note, (12) argued that it may be possible to isolate an 'ideal probiotic', but only if proper screening methods are used to identify the above listed 'ideal' traits. They suggested that in vivo efficacy testing be conducted only on strains thus selected to possess these 'ideal' traits. Barrow (13) on the other hand expressed concern about the high degree of variability observed when in vivo probiotic efficacy tests are conducted. How can probiotic efficacy of any strain be determined if the tests used to determine efficacy are unreliable owing to this high degree of variability? He attributes this variability, among other factors, to poor characterization of the strains used in the past and/or poor understanding of the microecology of the GI tract, positing that efficacy evaluations conducted using strains lacking either 'ideal' traits or host specificity are not likely to succeed in any event. And furthermore, that in too many instances, the occasional 'positive' results obtained are often over-optimistically, naively.

#### **Role of *L. reuteri* in Gut Health of Infants**

From birth to six months of age, approximately one out of two infants develops at least one functional gastrointestinal disorder (FGID) or related signs and symptoms. FGIDs such as infantile colic, regurgitation, functional diarrhea, and functional constipation are common worldwide, but their prevalence rates vary extensively (16). *L. reuteri* is beneficial to the host's

health as it enables the colonization of the gut with beneficial bacteria. This occurs because *L. reuteri* strains are resistant to low pH and bile salts. These strains can attach to mucin and intestinal epithelia because they can produce exopolysaccharides (EPS), which are important for biofilm formation. The formation of biofilms helps *L. reuteri* to adhere to epithelial surfaces and enhances the probiotic effects of *L. reuteri* (15, 17). Antimicrobial metabolites produced by *L. reuteri* such as reuterin inhibit a wide range of microorganisms, particularly gram-negative bacteria. Other metabolites such as lactic acid, acetic acid, ethanol, and reutericyclin are effective against numerous pathogenic bacteria. One of the key roles of the probiotic *L. reuteri* strain is to promote mucosal barrier functions by reducing bacterial translocation from the GI tract to the mesenteric lymph nodes. Apart from gut health, *L. reuteri* interacts with the gut-brain axis and modulates the afferent sensory nerves that influence gut motility (15, 18). The possible modes of action by which probiotic *L. reuteri* helps in the management of FGIDs are as follows (14,15, 18):

- (i) *L. reuteri* improves gut motility, which reduces constipation and relieves functional abdominal pain. It also increases colonic contractility.
- (ii) *L. reuteri* modulates the gut's immune and inflammatory responses, which reduces the incidence of infections such as diarrhea.
- (iii) *L. reuteri* inhibits the visceral pain pathway and thus may have a role in relieving functional abdominal pain.
- (iv) *L. reuteri* reduces gastric distension and accelerates gastric emptying and thus helping reduce the frequency of regurgitation.

#### **Probiotic Properties of *L. reuteri***

There are some prerequisites for becoming potential probiotics: to survive in low pH and enzyme-enriched environments, to adhere to epithelium for host-probiotic interaction, competition with pathogenic microorganisms, and most importantly, safety. *L. reuteri* meets all of these requirements. Here, additional probiotic properties of *L. reuteri* are discussed that contribute to its diverse beneficial effects on host health and disease prevention and/or amelioration. [19]

#### **Gut Colonization of *L. reuteri***

Built for digestion and absorption, some sites of the GI system have developed to be harsh for microorganism colonization. Examples of this can be seen in the low pH conditions caused by gastric acids and bile salts in upper small intestine.

Thus, the very first step of colonizing the GI tract is to survive in such environments. Multiple *L. reuteri* strains are resistant to low pH and bile salts. This resistance is believed to be at least partially dependent on its ability to form biofilms. *L. reuteri* is capable of attaching to mucin and intestinal epithelia, and some strains can adhere to gut epithelial cells in a range of vertebrate hosts. [19]

A possible mechanism for adherence is the binding of bacterial surface molecules to the mucus layer. Mucus-binding proteins (MUBs) and MUB-like proteins, encoded by *Lactobacillus*-specific clusters of orthologous protein coding genes, serve as adherence mediators, or so-called adhesins. [20]

The considerable diversity of MUBs among *L. reuteri* strains and the variation in the abundance of cell-surface MUBs significantly correlates with their mucus binding ability. [21]

The strain-specific role of MUBs in recognizing mucus elements and/or their capability of promoting aggregation can explain the contribution of MUBs on the adherence of *L. reuteri*. Factors that mediate the attachment to the surfaces include multiple large surface proteins. [22]

As *L. reuteri* has colonized the host GI tract to form biofilms, efforts have been made to study the regulation of *L. reuteri* biofilm secretion and its association with the adherence of bacteria to host GI epithelium. By doing *in vitro* biofilm assay, uncovered the contribution of GtfA and Inu in the biofilm formation of *L. reuteri* TMW1.106. [23]

The *in vivo* biofilm formation of *L. reuteri* strains seems to be dependent on the host origin of the strains. In one study, nine *L. reuteri* strains isolated from different hosts (human, mouse, rat, chicken, and pig) were given to germ-free mice and the biofilms were evaluated after 2 days. Interestingly, only rodent strains were able to form biofilms and adhere to the forestomach epithelium, although the luminal populations were comparable among strains of different origins. [24]

Another study by the same authors showed that a specialized transport pathway (the SecA2-SecY2 system) was unique in the rodent and porcine strains. [25]

By using a rodent strain *L. reuteri* 100-23, they compared extracellular and cell wall-associated proteins between the wild-type strain and the secA2 mutant. Only one surface protein, *L. reuteri* 70902, was absent in the secA2 mutant. *In vivo* colonization studies showed that the absence of *L. reuteri* 70902 leads to almost completely

eliminated biofilm formation. This strongly suggests that *L. reuteri* 70902 and the SecA2-SecY2 system are key factors regulating biofilm production from *L. reuteri* 100-23 in germ-free mice. [26]

Another group investigated the role of two-component systems bfrKRT and cemAKR in *in vitro* biofilm formation of *L. reuteri* 100-23. They found the deletion of certain genes in the operons enhanced. [27]

### Health-Promoting Effect

The antimicrobial and immunomodulatory effects of *L. reuteri* strains are linked to their metabolite production profile. Here, we discuss a few well-studied metabolites with regard to the probiotic potential of *L. reuteri*.

### Reuterin

Most *L. reuteri* strains of human and poultry lineage are able to produce and excrete reuterin, a well-known antimicrobial compound. Apart from reuterin, several other antimicrobial substances, including lactic acid, acetic acid, ethanol, and reutericyclin, have been determined as products of some *L. reuteri* strains. With the synthesis of these substances, *L. reuteri* has been shown to be effective against a variety of GI bacterial infections. These infections include *Helicobacter pylori*, *E. coli*, *Clostridium difficile*, and *Salmonella*. One of the more notable illustrations of the efficacy of *L. reuteri* as a probiotic against infections is the use of *L. reuteri* to treat *H. pylori*. *H. pylori* infection is a major cause of chronic gastritis and peptic ulcers, as well as a risk factor for gastric malignancies. The use of *L. reuteri* against *H. pylori* has been explored in many studies. It has been suggested that *L. reuteri* works by competing with *H. pylori* and inhibiting its binding to glycolipid receptors. The competition reduces the bacterial load of *H. pylori* and decreases the related symptoms. Some studies have shown that *L. reuteri* has the potential to completely eradicate *H. pylori* from the intestine. Importantly, *L. reuteri* is advantageous in the treatment of *H. pylori* as the supplementation eradicates the pathogen without causing the common side effects associated with antibiotic therapy.

### Histamine

The amino acid L-histidine, which is a dietary component, can be converted by certain strains of *Lactobacillus reuteri* into the biogenic amine histamine. The model strain for the investigation of histamine in *L. reuteri* was *L.*



reuteri 6475, a human commensal bacterium. Histamine produced from *L. reuteri* 6475 was shown by J. Versalovic's group to inhibit the generation of tumour necrosis factor (TNF) in activated human monocytes. The histamine H2 receptor's activation, elevated intracellular cAMP and protein kinase A, and inhibition of MEK/ERK signalling were all necessary for this suppression. The entire chromosomal histidine decarboxylase (*hdc*) gene cluster, which consists of *hdcA*, *hdcB*, and *hdcP*, controls the synthesis of histamine and the ensuing in vitro TNF suppressing activity. Full chromosomal histidine decarboxylase (*hdc*) gene cluster, comprising *hdcA*, *hdcB*, and *hdcP*, controls histamine production and, consequently, its ability to reduce TNF in vitro. In a mouse colitis model induced by trinitrobenzene sulfonic acid (TNBS), the same team of researchers also discovered that oral administration of *hdc*+ *L. reuteri* could successfully control intestinal inflammation. Furthermore, colitis mitigation was observed when *L. reuteri* 6475 culture supernatant was injected intraperitoneally into mice treated with TNBS. These findings clearly demonstrate the role of histamine and other *L. reuteri* metabolites in intestinal immunomodulation.

### Vitamins

Since the human body cannot synthesise any of the vitamins, there are thirteen that are vital to human health. Numerous *L. reuteri* strains, like many other *Lactobacillus* species, are capable of producing several vitamins, such as vitamin B9 (folate) and vitamin B12 (cobalamin). Because a B12-dependent coenzyme is needed for the reduction of glycerol to 3-HPA, as was previously indicated, B12 is essential for the synthesis of reuterin. Thus far, B12 has been detected in at least 4 different origin *L. reuteri* strains. The two most researched strains of *L. reuteri* are *L. reuteri* JCM1112 and CRL1098. In one study, it was demonstrated that giving *L. reuteri* CRL1098 along with a diet deficient in vitamin B12 might improve pathologies in pregnant female mice who were B12 deficient, as well as in their offspring. This finding clearly indicates the possible use of *L. reuteri* in the treatment of B12 deficiency. Certain strains of *Lactobacillus reuteri*, such as *L. reuteri* 6475 and *L. reuteri* JCM1112, have the ability to synthesise folate in addition to B12.

### REFERENCE:

- [1]. MD. Jahangir Alam, et al., Role of Probiotic *Lactobacillus reuteri* in Improving Gut Health and Immunity in Infants and Toddlers: A review International Journal of Nutrition Science, 7(2):75-80, 2022. doi: 10.30476/IJNS.2022.94849.1182
- [2]. Zihan Yu, et al., The role of potential probiotic strains *Lactobacillus reuteri* in various intestinal diseases: New roles for an old player, *Frontier Microbiology*, 14, 2023, <https://doi.org/10.3389/fmicb.2023.1095555>
- [3]. Dhivya K, et al., The Therapeutic Effects of *Lactobacillus reuteri* Supplementation in Various Conditions: A Systematic Review, *Journal of Pharmaceutical Research International*, 35 (25): 26-46, 2023.
- [4]. Monica L. Nation, et al., Impact of *Lactobacillus reuteri* colonization on gut microbiota, inflammation, and crying time in infant colic, *Scientific Report*, 7:15047, 2017.
- [5]. Gang Wang, et al., *Lactobacillus reuteri* improves the development and maturation of fecal microbiota in piglets through mother-to-infant microbe and metabolite vertical transmission, *Microbiome*, 10 (211): 1-21, 2022.
- [6]. Ivan A., et al., Validation of the Probiotic Concept: *Lactobacillus reuteri* Confers Broad-spectrum Protection against Disease in Humans and Animals, *Microbial ecology in health and disease*, 12 (4), 247-285, 2000.
- [7]. Gabriela Sinkiewicz, *Lactobacillus Reuteri* in Health and Disease, Malmö University Health and Society Doctoral Dissertations, 3, 2010.
- [8]. Abediankenari, et al., Generation of immune inhibitory dendritic cells and CD4+T regulatory cells inducing by TGF-beta, *Iranian Journal of Allergy, Asthma Immunology*, 8, 25-30, 2009.
- [9]. Abhisingha, et al., Selection of potential probiotic *Lactobacillus* with inhibitory activity against *Salmonella* and fecal coliform bacteria. *Probiotics Antimicrobial Proteins*, 2017.
- [10]. Abrahamsson, et al., No effect of probiotics on respiratory allergies: a seven-year follow-up of a randomized controlled trial in infancy, *Pediatric Allergy and Immunology*, 24, 556-561, 2013.
- [11]. Tannock GW. Genetic manipulation of gut microorganisms. In: Fuller R, ed.

- Probiotics: the Scientific Basis. London: Chapman and Hall, 1992.
- [12]. Havenaar R, Huisin't Veld JHJ. Probiotics: a general view. In: Wood BJB, ed. The lactic acid bacteria.v. 1.The lactic acid bacteria in health and disease. New York: Elsevier Applied Science, 1992: 209–24.
- [13]. Barrow PA. Probiotics for chickens. In: Fuller R, editor. Probiotics: the scientific basis. London: Chapman andHall, 1992: 225–57.
- [14]. Srinivasan R, Kesavelu D, Veligandla KC, et al. Lactobacillus reuteri DSM 17938: Review of evidence in functional gastrointestinal disorders. *PediatrTher*. 2018.
- [15]. Mu Q, Tavella VJ, Luo XM. Role of Lactobacillus reuteri in Human Health and Diseases. *Front Microbiol*. 2018;9:757.
- [16]. Vandenplas Y, Hauser B, Salvatore S. Functional Gastrointestinal Disorders in Infancy: Impact on the Health of the Infant and Family. *PediatrGastroenterolHepatolNutr*. 2019; 22:207–216.
- [17]. Saviano A, Brigida M, Migneco A, et al. Lactobacillus Reuteri DSM 17938 (Limosi Lactobacillus reuteri) in diarrhea and constipation: Two sides of the same coin? *Medicina*. 2021; 57:643.
- [18]. Indrio F, Riezzo G, Raimondi F, et al. Lactobacillusreuteri accelerates gastric emptying and improves regurgitation in infants. *Eur J Clin Invest*. 2011;41:417-22.
- [19]. Li X. J., Yue L. Y., Guan X. F., Qiao S. Y., The adhesion of putative probiotic lactobacilli to cultured epithelial cells and porcine intestinal mucus. *J. Appl. Microbiol*. 104 (4), 2008.
- [20]. Gunning A. P., Kavanaugh D., Thursby E., Etzold S., MacKenzie D. A., Juge N. (2016). Use of atomic force microscopy to study the multi-modular interaction of bacterial adhesins to mucins. *Int. J. Mol. Sci*. 17:E1854. 10.3390/ijms17111854
- [21]. Mackenzie D. A., Jeffers F., Parker M. L., Vibert-Vallet A., Bongaerts R. J., Roos S., et al. (2010). Strain-specific diversity of mucus-binding proteins in the adhesion and aggregation properties of Lactobacillus reuteri. *Microbiology* 156(Pt 11) 3368–3378. 10.1099/mic.0.043265-0
- [22]. Walter J., Chagnaud P., Tannock G. W., Loach D. M., Dal Bello F., Jenkinson H. F., et al. (2005). A high-molecular-mass surface protein (Lsp) and methionine sulfoxidereductase B (MsrB) contribute to the ecological performance of Lactobacillus reuteri in the murine gut. *Appl. Environ. Microbiol*. 71 979–986. 10.1128/AEM.71.2.979-986.2005 [PMC free article] [PubMed] [CrossRef] [Google Scholar] [Ref list]
- [23]. Walter J., Schwab C., Loach D. M., Ganzle M. G., Tannock G. W. (2008). Glucosyltransferase A (GtfA) and inulosucrase (Inu) of Lactobacillus reuteri TMW1.106 contribute to cell aggregation, in vitro biofilm formation, and colonization of the mouse gastrointestinal tract. *Microbiology* 154(Pt 1) 72–80.
- [24]. Frese S. A., Mackenzie D. A., Peterson D. A., Schmaltz R., Fangman T., Zhou Y., et al. (2013). Molecular characterization of host-specific biofilm formation in a vertebrate gut symbiont. *PLoS Genet*. 9:e1004057. 10.1371/journal.pgen.1004057 [PMC free article] [PubMed] [CrossRef] [Google Scholar] [Ref list]
- [25]. Frese S. A., Benson A. K., Tannock G. W., Loach D. M., Kim J., Zhang M., et al. (2011). The evolution of host specialization in the vertebrate gutsymbiont Lactobacillus reuteri. *PLoS Genet*. 7.
- [26]. Frese S. A., Mackenzie D. A., Peterson D. A., Schmaltz R., Fangman T., Zhou Y., et al. (2013). Molecular characterization of host-specific biofilm formation in a vertebrate gut symbiont. *PLoS Genet*. 9
- [27]. Su M. S., Ganzle M. G. (2014). Novel two-component regulatory systems play a role in biofilm formation of Lactobacillus reuteri rodent isolate 100-23. *Microbiology* 160(Pt 4) 795–806.
- [28]. Qinghui Mu, et al., Role of Lactobacillus reuteri in Human Health and Diseases, *frontiers in microbiology*, 2018; 9: 757.
- [29].